A real-world study on the efficacy and safety of ondansetron oral dissolving film in preventing chemotherapy, radiotherapy, and postoperative nausea and vomiting
Phase 4
Recruiting
- Conditions
- Vomit
- Registration Number
- ChiCTR2400089063
- Lead Sponsor
- Jiangsu Cancer Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
(1) Age and gender are not limited;<br>(2) Patients receiving chemotherapy; radiotherapy; surgery;<br>(3) Use ondansetron orally dissolving film for at least 3 days;
Exclusion Criteria
(1) The researcher determines any situation that is unstable or may endanger the subject’s safety and compliance with the study;<br>(2) Pregnant or lactating women;<br>(3) Are allergic to study drugs and excipients or have had severe adverse reactions before;
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence and severity of nausea and vomiting in the acute phase (during 24 hours after chemotherapy/radiotherapy/surgery);
- Secondary Outcome Measures
Name Time Method Incidence and severity of nausea and vomiting in patients in the delayed period (48-72 hours after chemotherapy/radiotherapy/surgery);PRO;Safety;